Nicotinic Receptor Alpha 7 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| CHRNA7 |
|---|
| Protein Name | Nicotinic Cholinergic Receptor Alpha 7 |
|---|
| Gene | CHRNA7 |
|---|
| UniProt ID | P36544 |
|---|
| PDB IDs | 7EKO, 6M1H |
|---|
| Molecular Weight | 56.5 kDa |
|---|
| Subcellular Localization | Plasma Membrane |
|---|
| Protein Family | Cys-Loop Receptor, Nicotinic Acetylcholine Receptor |
|---|
The CHRNA7 protein forms a homomeric pentameric ligand-gated ion channel. Each subunit contains an extracellular N-terminal domain with the characteristic Cys-loop motif, followed by four transmembrane domains (TM1-TM4). The channel pore is formed by the TM2 helices, which line the ion conduction pathway. Each subunit has a molecular weight of approximately 56 kDa. The receptor contains binding sites for acetylcholine and nicotine at the interfaces between subunits. The receptor has high permeability to calcium ions (PCa/PNa ~ 6-10), making it particularly important for calcium-dependent signaling.
The α7 nicotinic acetylcholine receptor (nAChR) is a ligand-gated ion channel that rapidly conducts Na+, K+, and most importantly Ca2+ ions upon acetylcholine or nicotine binding. Key functions include:
- Fast excitatory neurotransmission in the central nervous system
- Modulation of neurotransmitter release (dopamine, glutamate, GABA, acetylcholine)
- Regulation of neuronal excitability and synaptic plasticity
- Involvement in attention, learning, and memory processes
- Immune system modulation through macrophage and microglial expression
α7 nAChR expression in the brain and immune system:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons and interneurons
- Cortex: Wide expression across layers, particularly layer VI
- Basal Forebrain: Expression in cholinergic neurons
- Thalamus: Moderate expression in relay nuclei
- Microglia: Functional expression for neuroimmune modulation
- Lymphocytes: Immune cell expression for inflammatory regulation
CHRNA7 is critically implicated in neurodegenerative diseases:
- Loss of α7 nAChRs correlates with cognitive decline
- Aβ1-42 directly binds to α7 receptors, disrupting function
- Protects against excitotoxicity and oxidative stress
- Modulates amyloid precursor protein processing
- Loss in dopaminergic neurons contributes to dysfunction
- Neuroprotective effects of α7 agonists
- May modulate neuroinflammation in substantia nigra
- CHRNA7 deletions associated with schizophrenia risk
- Auditory gating deficits in schizophrenia related to α7 dysfunction
- Target for cognitive enhancement therapies
- Altered expression in motor neurons
- Potential therapeutic target for neuroprotection
- Agonists: PHA-543613, ABT-107, JNJ-39393406 for cognitive enhancement
- Positive Allosteric Modulators: PNU-120596, desformylflustrabromine
- Partial Agonists: GTS-21 (DMX-B)
- Cognitive dysfunction in Alzheimer's and schizophrenia
- Neuroprotection in Parkinson's disease
- Inflammatory conditions (microglial modulation)
- Pain management (analgesic potential)
- Development of brain-penetrant selective α7 agonists
- Understanding Aβ-α7 receptor interactions
- Biomarker development for receptor density
- Gene therapy for CHRNA7 expression restoration
The study of Nicotinic Receptor Alpha 7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Albuquerque EX, et al. (2009). Properties and therapeutic potential of alpha7 nAChRs. Biochemical Pharmacology. PMID:19303438
- Levin ED (2013). α7-nicotinic receptors and cognition. Current Drug Targets. PMID:23029589
- Liu Q, et al. (2012). α7 nAChR agonists for AD treatment. Expert Opinion on Therapeutic Patents. PMID:22494433
- Changeux JP (2012). The nicotinic acetylcholine receptor. Nature Reviews Neuroscience. PMID:21048584
- Wallace TL, Porter RH (2011). Targeting the nicotinic alpha7 acetylcholine receptor. Biochemical Pharmacology. PMID:21871911